Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?

Luke Maese, Carmelo Rizzari, Russell Coleman, Austin Power, Inge van der Sluis, Rachel E. Rau

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

16 Citaten (Scopus)


Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Bacterial L-asparaginase has played an important role in ALL treatment for several decades; however, hypersensitivity reactions to Escherichia coli-derived asparaginases often preclude their use. Inability to receive asparaginase due to hypersensitivities is associated with poor patient outcomes. Erwinia chrysanthemi-derived asparaginase (ERW) is an effective, non-cross-reactive treatment option, but is limited in supply. Consequently, alternative asparaginase preparations are needed to ensure asparaginase availability for patients with hypersensitivities. Recombinant technology can potentially address this unmet need by programming cells to produce recombinant asparaginase. JZP-458, a recombinant Erwinia asparaginase derived from a novel Pseudomonas fluorescens expression platform with no immunologic cross-reactivity to E. coli-derived asparaginases, has the same primary amino acid sequence as ERW, with comparable activity based on in vitro measurements. The efficient manufacturing of JZP-458 would provide an additional asparaginase preparation for patients with hypersensitivities.

Originele taal-2Engels
TijdschriftPediatric Blood and Cancer
Nummer van het tijdschrift10
StatusGepubliceerd - okt. 2021


Duik in de onderzoeksthema's van 'Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?'. Samen vormen ze een unieke vingerafdruk.

Citeer dit